innovation – Page 2

GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.

2024 Biotech IPOs: Insights and Trends

8 months ago talkbio0Tagged 2024, biopharma sector, biotech, Capital, Health care facility, innovation, Investments, IPO, IPOs, public entity, trends qualifier, venture

Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.

Dimension Secures $500M for Second Fund, Focusing on the Intersection of Science and Technology

8 months ago talkbio0Tagged Aortic Valve Insufficiency, biotech, Capital, Dimensions, innovation, Machine Learning, Science, Technology, venture

Dimension, Venture Capital, Science, Technology, Biotech, AI, Machine Learning, Life Sciences, Innovation

Empowering Women in Life Sciences: 2024’s Trailblazers in Biopharma R&D

8 months ago talkbio0Tagged 2024, Biological Science Disciplines, Biopharma, Fiercest, Gender, Health care facility, innovation, R&D, Women

Women in Life Sciences, Biopharma R&D, 2024’s Fiercest Women, Gender Balance, Innovation in Healthcare

AvenCell Therapeutics Secures $112 Million Series B Funding for Revolutionary ‘Switchable’ CAR-T Cell Therapy

9 months ago talkbio0Tagged AvenCell Therapeutics, biotech, CAR-T, CAR-Ts, Cell Therapy, Clinical Trials, innovation, Series B, Switchable

AvenCell Therapeutics, Series B Funding, CAR-T Cell Therapy, Switchable CAR-Ts, Clinical Trials, Biotech Innovation

Eli Lilly Expands Global Innovation Reach with New Research Centers in China

9 months ago talkbio0Tagged Biotechnology, China, Drug Development, Eli, Eli Lilly, Gateway, innovation, Research Organization

Eli Lilly, China, Research Centers, Innovation, Gateway Labs, Biotechnology, Drug Development

CMS Unveils Preliminary List of 101 Generic Drugs for Medicare $2 Out-of-Pocket Plan

10 months ago talkbio0Tagged Adherence (attribute), Drug List, Expenditures, Out-of-Pocket, Health Outcomes, innovation, Medicare, Myasthenic Syndromes, Congenital

Medicare $2 Drug List Model, generic drugs, out-of-pocket costs, medication adherence, health outcomes, CMS Innovation Center